A5024548789- Cervical Cancer and HPV Research
- Colorectal Cancer Screening and Detection
- Global Cancer Incidence and Screening
- COVID-19 and healthcare impacts
- Cancer Diagnosis and Treatment
- Healthcare Policy and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Healthcare cost, quality, practices
- Biosimilars and Bioanalytical Methods
- Head and Neck Cancer Studies
MSD (UK) Limited (United Kingdom)
2024
Novartis (United Kingdom)
2022
Aim: To analyze the impact of COVID-19 pandemic on US healthcare resource utilization. Methods: Optum claims data were used to compare all-cause visits and spending for selected diseases between prepandemic periods. Telemedicine use was only assessed period owing availability. Results: During first wave pandemic, across all disease areas displayed a rapid decline compared with period, followed by recovery. A reduction in outpatient home observed, whereas inpatient prescription increased....
BACKGROUND Human papillomavirus (HPV) causes several cancers such as cervical cancer and some head neck (oral cavity, pharynx, larynx), vulval, vaginal, anal, penile cancers. As HPV vaccination is available, there potential to prevent these attributed consequently the burden associated with them. The aim of this analysis was estimate number HPV-related deaths productivity costs due years life lost (YLL) in United Kingdom (UK).
Patients who have been treated for high-grade cervical intraepithelial neoplasia (CIN grade ≥2) are at a high risk subsequent CIN and other cancers diseases related to human papillomavirus (HPV). HPV vaccination can reduce the of disease in patients surgically 2 or greater CIN; however, there is no formal recommendation prophylactic this high-risk population, cost-effectiveness unknown.